Market Research Logo

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2015

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2015’, provides an overview of the Post-Traumatic Stress Disorder (PTSD)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Post-Traumatic Stress Disorder (PTSD) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Post-Traumatic Stress Disorder (PTSD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Post-Traumatic Stress Disorder (PTSD) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Post-Traumatic Stress Disorder (PTSD) Overview
Therapeutics Development
Pipeline Products for Post-Traumatic Stress Disorder (PTSD) - Overview
Pipeline Products for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis
Post-Traumatic Stress Disorder (PTSD) - Therapeutics under Development by Companies
Post-Traumatic Stress Disorder (PTSD) - Therapeutics under Investigation by Universities/Institutes
Post-Traumatic Stress Disorder (PTSD) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Post-Traumatic Stress Disorder (PTSD) - Products under Development by Companies
Post-Traumatic Stress Disorder (PTSD) - Products under Investigation by Universities/Institutes
Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Azevan Pharmaceuticals, Inc.
Catalyst Pharmaceutical Partners, Inc.
Humanetics Corporation
Intra-Cellular Therapies, Inc.
Marinus Pharmaceuticals, Inc.
Nanotherapeutics, Inc.
Neuralstem, Inc.
Neurocrine Biosciences, Inc.
NeuroNascent, Inc.
Omeros Corporation
Otsuka Holdings Co., Ltd.
Polleo Pharma Limited
Tonix Pharmaceuticals Holding Corp.
Vanda Pharmaceuticals Inc.
Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
7-Keto - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ADX-71743 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
brexpiprazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CPP-115 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug for Post-Traumatic Stress Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Inhibit FAAH for CNS Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ganaxolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
iloperidone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ITI-007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NNI-351 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NSI-189 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NTC-942 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rycal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-107 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Target GPR151 for CNS Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for BED and PTSD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Post-Traumatic Stress Disorder - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit mGluR7 For Central Nervous System Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SRX-246 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SRX-251 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TNX-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for Post-Traumatic Stress Disorder and Depression - Drug Profile
Product Description
Mechanism of Action
R&D Progress
verucerfont - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vigabatrin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZL-006 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Post-Traumatic Stress Disorder (PTSD) - Recent Pipeline Updates
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects
Post-Traumatic Stress Disorder (PTSD) - Discontinued Products
Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones
Featured News & Press Releases
Jun 10, 2014: Tonix Pharmaceuticals Receives IND Clearance From U.S. Food and Drug Administration for TNX-102 SL in Post-Traumatic Stress Disorder
Oct 11, 2013: Tonix Pharmaceuticals to Participate in the Women's Healthcare Innovation and Leadership Showcase on October 15, 2013
Aug 19, 2013: Tonix Pharmaceuticals Presents Nonclinical Results at the Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome
Oct 24, 2012: Tonix Pharma Completes Pre-IND Meeting With FDA For Potential New Treatment For Post-Traumatic Stress Disorder
Oct 15, 2012: Indiana University Scientists Discover New Drug For Preventing Post-Traumatic Stress Disorder
Aug 30, 2012: Armgo Pharma Announces Publication Of Data Related To New Approach For Treatment Of Stress-Induced Cognitive Disorders
May 23, 2012: Nanotherapeutics Initiates Phase II Clinical Trial Of PRX-3140 For Treatment Of Post Traumatic Stress Disorder
Jun 20, 2011: Neuralstem On Schedule To Complete Phase Ia Trial Of NSI-189 In Major Depression
Apr 21, 2011: Marinus Announces Commencement Of Phase II Trial Of Ganaxolone In Posttraumatic Stress Disorder
Apr 07, 2011: Marinus Receives US Patent For Ganaxolone
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2015
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd, H1 2015
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals, Inc., H1 2015
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2015
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Humanetics Corporation, H1 2015
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Intra-Cellular Therapies, Inc., H1 2015
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Marinus Pharmaceuticals, Inc., H1 2015
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Nanotherapeutics, Inc., H1 2015
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neuralstem, Inc., H1 2015
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neurocrine Biosciences, Inc., H1 2015
Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent, Inc., H1 2015
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corporation, H1 2015
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co., Ltd., H1 2015
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Polleo Pharma Limited, H1 2015
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2015
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Vanda Pharmaceuticals Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Post-Traumatic Stress Disorder (PTSD) Therapeutics - Recent Pipeline Updates, H1 2015
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H1 2015
Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2015
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report